VERAXA Biotech AG (NASDAQ: VRXA) has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer, reinforcing the company's focus on advancing its proprietary BiTAC(R) technology platform. The leadership change comes as VERAXA prepares its lead oncology programs for clinical development, with recent regulatory feedback from Germany's Paul-Ehrlich-Institute providing additional clarity for the company's lead BiTAC(R)-TCE program.
Dr. Erkel previously served as Vice President of Research & Development at VERAXA, where he helped oversee development of the company's antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company's BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward clinical trials. VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
The appointment underscores VERAXA's commitment to advancing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. Investors are closely watching companies developing such therapies, and VERAXA's strengthened scientific leadership may signal progress in its pipeline. The company's BiTAC(R) platform is designed to create conditionally active bispecific antibodies that target tumor cells while minimizing off-target effects.
For more information on VERAXA Biotech and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA.
